ArticleThe Korean journal of internal medicine2015
Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience.
Article in The Korean journal of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Isolated jejunal amyloidosis presenting as acute mechanical small bowel obstruction: a rare diagnostic challenge - a case report.International journal of surgery case reports · 2026Article
- Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis.Blood advances · 2026Article
- Article
- Endoscopic Features of Gastrointestinal Amyloidosis: A Proposed Endoscopic Classification.Gut and liver · 2025Article
- Endoscopic and pathological characteristics of gastrointestinal amyloidosis: a retrospective analysis.BMC gastroenterology · 2025Article
- A Rare Case with Recurrent Abdominal Pain as the First Symptom: AL Amyloidosis with Colon Involvement Combined with Pulmonary Adenocarcinoma.Journal of inflammation research · 2025Article
- Idiopathic AA amyloidosis presenting with initial abdominal pain: a case report and literature review.Frontiers in medicine · 2025Article
- Gastrointestinal amyloidosis in a 50-year-old patient with miliary tuberculosis: A case report.Clinical case reports · 2024Article
- Chronic underlying gastrointestinal amyloidosis was revealed by cardiac echography: a case report from Syria.Annals of medicine and surgery (2012) · 2024Article
- Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review.Journal of clinical medicine · 2024Review
- Teduglutide in amyloidosis-associated intestinal failure.Clinical case reports · 2023Article
- Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report.Yonsei medical journal · 2023Article
- Peritoneal Amyloid as a Presenting Manifestation of AL Amyloid.Journal of community hospital internal medicine perspectives · 2023Article
- Article
- Endoscopic diagnosis of chronic diarrhea.DEN open · 2022Review
- Gastrointestinal amyloidosis in a patient with smoldering multiple myeloma: A case report.World journal of clinical cases · 2022Article
- A Case of Systemic AL Amyloidosis Diagnosed by Screening Colonoscopy.Case reports in gastrointestinal medicine · 2022Article
- Gastric amyloidosis presenting as acute upper gastrointestinal bleeding: a case report.BMC gastroenterology · 2021Article
- Systemic Immunoglobulin Light Chain Amyloidosis Involving the Large Intestine.ACG case reports journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe gastrointestinal (GI) tract often becomes involved in patients with systemic amyloidosis. As few GI amyloidosis data have been reported, we describe the clinical features and outcomes of patients with pathologically proven GI amyloidosis.
methodsWe identified 155 patients diagnosed with systemic amyloidosis between April 1995 and April 2013. Twenty-four patients (15.5%) were diagnosed with GI amyloidosis using associated symptoms, and the diagnoses were confirmed by direct biopsy.
resultsAmong the 24 patients, 20 (83.3%) had amyloidosis light chain (AL), three (12.5%) had amyloid A, and one (4.2%) had transthyretin-related type amyloidosis. Their median age was 57 years (range, 37 to 72), and 10 patients were female (41.7%). The most common symptoms of GI amyloidosis were diarrhea (11 patients, 45.8%), followed by anorexia (nine patients, 37.5%), weight loss, and nausea and/or vomiting (seven patients, 29.2%). The histologically confirmed GI tract site in AL amyloidosis was the stomach in 11 patients (55.0%), the colon in nine (45.0%), the rectum in seven (35.0%), and the small bowel in one (5.0%). Patients with GI involvement had a greater frequency of organ involvement (p = 0.014). Median overall survival (OS) in patients with GI involvement was shorter (7.95 months; range, 0.3 to 40.54) than in those without GI involvement (15.84 months; range, 0.0 to 114.53; p = 0.069) in a univariate analysis. A multivariate analysis of prognostic factors for AL amyloidosis revealed that GI involvement was not a significant predictor of OS (p = 0.447).
conclusionsThe prognosis of patients with AL amyloidosis and GI involvement was poorer than those without GI involvement, and they presented with more organ involvement and more advanced disease than those without organ involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.